First New York Securities’s Merrimack Pharmaceuticals, Inc. MACK Stock Holding History

First New York Securities’s Portfolio MACK Stock Details MACK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-477	Closed	-$23.8K	–	249
2016 Q3	$23.8K	Buy	+477	New	+$19.8K	0.02%	160
2014 Q4	–	Sell	-318	Closed	-$21.9K	–	601
2014 Q3	$21.9K	Buy	+318	New	+$17K	0.02%	330

Other funds holding MACK

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

CCM

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

TIAA CREF Investment Management New York $141B AUM 14.18% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

First New York Securities's MACK Position: Q4 2016 in Review

First New York Securities sold out of Merrimack Pharmaceuticals, Inc. (MACK) in Q4 2016, closing a stake of 477 shares — an estimated $23.8K sold.

First New York Securities first reported a position in MACK in Q3 2014 and held it in 2 quarters. The position peaked at $23.8K in Q3 2016. 136 funds tracked by Wall St. Rank hold MACK as of Q4 2016.

First New York Securities reported no remaining Merrimack Pharmaceuticals, Inc. position as of Q4 2016 after selling out during the quarter.
First New York Securities sold 477 Merrimack Pharmaceuticals, Inc. shares in Q4 2016, an estimated $23.8K.
First New York Securities first reported a position in Merrimack Pharmaceuticals, Inc. in Q3 2014 and held it in 2 quarters.
First New York Securities's Merrimack Pharmaceuticals, Inc. position peaked at $23.8K in Q3 2016.
136 funds tracked by Wall St. Rank held Merrimack Pharmaceuticals, Inc. as of Q4 2016.

Based on First New York Securities's 13F filing for Q4 2016, filed 7 Feb 2017.